- Home
- APM vs OVID Comparison
APM vs OVID Comparison
Compare APM & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- OVID
- Stock Information
- Founded
- APM 2010
- OVID 2014
- Country
- APM United Kingdom
- OVID United States
- Employees
- APM N/A
- OVID N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- OVID Health Care
- Exchange
- APM Nasdaq
- OVID Nasdaq
- Market Cap
- APM 18.9M
- OVID 20.6M
- IPO Year
- APM 2018
- OVID 2017
- Fundamental
- Price
- APM $1.85
- OVID $1.29
- Analyst Decision
- APM
- OVID Strong Buy
- Analyst Count
- APM 0
- OVID 4
- Target Price
- APM N/A
- OVID $3.13
- AVG Volume (30 Days)
- APM 20.3M
- OVID 1.9M
- Earning Date
- APM 04-30-2025
- OVID 08-13-2025
- Dividend Yield
- APM N/A
- OVID N/A
- EPS Growth
- APM N/A
- OVID N/A
- EPS
- APM N/A
- OVID N/A
- Revenue
- APM N/A
- OVID $6,651,000.00
- Revenue This Year
- APM N/A
- OVID $708.13
- Revenue Next Year
- APM N/A
- OVID N/A
- P/E Ratio
- APM N/A
- OVID N/A
- Revenue Growth
- APM N/A
- OVID 1070.95
- 52 Week Low
- APM $0.46
- OVID $0.24
- 52 Week High
- APM $7.49
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- APM 50.26
- OVID 77.40
- Support Level
- APM $2.17
- OVID $1.16
- Resistance Level
- APM $2.65
- OVID $1.30
- Average True Range (ATR)
- APM 0.36
- OVID 0.12
- MACD
- APM -0.05
- OVID 0.02
- Stochastic Oscillator
- APM 18.38
- OVID 90.55
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.